Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Novartis AG | 958 |
| 2 | Janssen Pharmaceutica NV | 345 |
| 3 | Bayer Pharma AG | 329 |
| 4 | Takeda Pharmaceutical Co Ltd | 205 |
| 5 | F Hoffmann La Roche AG | 183 |
| 6 | Pharmacia and Upjohn Co | 180 |
| 7 | Cartesian Therapeutics Inc | 136 |
| 8 | Kymera Therapeutics Inc | 124 |
| 9 | Sterix Ltd | 122 |
| 10 | Amgen Inc | 112 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 11,409 |
| 2 | A61K | Medicinal preparations | 10,659 |
| 3 | C07D | Heterocyclic compounds | 4,630 |
| 4 | C07J | 2,812 | |
| 5 | G01N | Investigating / analysing materials | 2,282 |
| 6 | C12N | Microorganisms, enzymes | 1,703 |
| 7 | C07K | Peptides | 1,468 |
| 8 | C12P | Fermentation, enzyme processes | 1,047 |
| 9 | C12Q | Measuring/testing involving enzymes | 987 |
| 10 | C07C | Acyclic and carbocyclic compounds | 913 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| 4-SUBSTITUTED ANDROSTENDIONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | 1986 | Pfizer Italia SRL | 30 |
| 4-amino androstendione derivatives and process for their preparation | 1988 | Pfizer Italia SRL | 29 |
| Method for preparing androstenedione by biodegradation of phytosterol in two-liquid-phase system | 2009 | ANHUI UNIVERSITY OF ARCHITECTURE | 18 |
| Extraction of 4-androstenedione from oil phase of fermenting liquid | 2005 | DISAINO MEDICINE DEVELOPMENT CO., LTD, SHANGHAI | 18 |
| Biofermentation method for androstendione by using resting cell | 2010 | Tianjin Jinyao Group Co., Ltd. | 17 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Hormonal and reproductive studies | 48 |
| 2 | Estrogen and related hormone effects | 35 |
| 3 | Ovarian function and disorders | 35 |
| 4 | Sexual Differentiation and Disorders | 15 |
| 5 | Reproductive Physiology in Livestock | 10 |
| 6 | Reproductive Biology and Fertility | 7 |
| 7 | Hormonal Regulation and Hypertension | 6 |
| 8 | Sexual function and dysfunction studies | 5 |
| 9 | Sperm and Testicular Function | 5 |
| 10 | Adrenal Hormones and Disorders | 4 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Frank Z. Stanczyk | University of Southern California | 63 |
| 2 | Fernand Labrie | Université Laval | 56 |
| 3 | Mitch Dowsett | Royal Marsden Hospital | 56 |
| 4 | Christopher Longcope | University of Massachusetts Chan Medical School | 30 |
| 5 | Jan-Ακε Gustafsson | Karolinska Institutet | 29 |
| 6 | R. J. Scaramuzzi | Commonwealth Scientific and Industrial Research Organisation | 27 |
| 7 | Angela Brodie | University of Maryland, Baltimore | 26 |
| 8 | L Stárka | Institute of Endocrinology | 26 |
| 9 | Mitsuteru Numazawa | Tohoku Medical and Pharmaceutical University | 25 |
| 10 | L. J. Spicer | Oklahoma State University | 22 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer | 2006 | 1082 | Prostate Cancer Treatment and Research |
| Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. | 2002 | 1041 | Ovarian function and disorders |
| Androgen Levels in Adult Females: Changes with Age, Menopause, and Oophorectomy | 2005 | 997 | Ovarian function and disorders |
| Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. | 1986 | 994 | Sperm and Testicular Function |
| Correlation of Hyperandrogenism with Hyperinsulinism in Polycystic Ovarian Disease* | 1980 | 920 | Ovarian function and disorders |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and structure of androstenedione?
Which organizations hold the most patents related to androstenedione?
What are the most prominent research topics associated with androstenedione in the scientific literature?
What are the key authors who have published the most research on androstenedione?
What patent classifications dominate the androstenedione patent landscape?